Close
4

Quotient Sciences Quotient Sciences

X

Company profile for Oxular

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
Oxular develops novel drug/device combination treatments for sight threatening retinal diseases. The Company’s innovative technology enables sustained drug release, better delivery, and reduced side effects, while improving therapeutic effectiveness. Strategic focus The global retinal therapeutics market is set to surpass $14 billion by 2024. Growth is being driven by: rising prevalence of retinal disease due to aging pop...
Oxular develops novel drug/device combination treatments for sight threatening retinal diseases. The Company’s innovative technology enables sustained drug release, better delivery, and reduced side effects, while improving therapeutic effectiveness. Strategic focus The global retinal therapeutics market is set to surpass $14 billion by 2024. Growth is being driven by: rising prevalence of retinal disease due to aging populations and the increasing incidence of diabetes; approval of new and longer lasting treatments; better drug delivery; & better access to healthcare globally Oxular’s development pipeline includes treatments.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
Oxular
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
Magdalen Centre, 1 Robert Robinson Avenue, Oxford OX4 4GA
Telephone
Telephone
+44 (0)1865 636200
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY